Home/Browse by collection/Clinical/Translational Cancer Immunotherapy

Clinical/Translational Cancer Immunotherapy

Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged. Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.

Showing results 21 - 30 of 100

Sorted by most recent

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-AresSee the full list of authors

12 February 2024